Breast CancerNCT00892515
Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer
A study testing exercise intervention, counseling intervention and gas chromatography in people with Breast Cancer and Healthy, no Evidence of Disease, run by Abramson Cancer Center at Penn Medicine at 1 site in United States.
Trial summary
RATIONALE: Exercise may change the risk of developing breast cancer. It is not yet known whether low-intensity exercise or high-intensity exercise is more effective in lowering the risk of breast cancer. Read more about this study
- Who is it for?
- Ages 18 to 35 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Breast Cancer, Healthy, no Evidence of Disease
- What is being tested?
- exercise intervention, counseling intervention and gas chromatography
- Type of treatment
- Surgery or procedure, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 183 participants
- Where
- 1 siteUnited States
- Study dates
- Oct 2008to 20 May 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- Healthy volunteers accepted
- Adult
DISEASE CHARACTERISTICS:
- Healthy women with ≥ 18% lifetime risk for breast cancer as evidenced by the following:
- Documentation from a genetic counselor of a known familial breast cancer susceptibility mutation
- Claus model risk of ≥18%
- Predicted probability of BRCA1/2 mutation > 25% based on the Myriad model
- Documentation of a known mutation in a family member such that the Mendelian probability of a BRCA1/2 mutation would be >25%
- History of lobular carcinoma in situ
- No prior prophylactic mastectomy
- Leisure-time exercise energy expenditure of ≤ 500 kcal/week over the past 6 months
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Premenopausal
- Menstrual cycles 25-32 days in length
- Intact ovaries and uterus
- Gynecologic age (defined as participant's current age minus the age at which she started menstruating) of at least 4 years
- Body mass index 21-50
- No history of menstrual difficulties
- No history of physician-diagnosed gynecological disease (e.g., fibroids, endometriosis, or polycystic ovary syndrome)
- Not pregnant
- Not planning to become pregnant during the study period
- No medical conditions or medications that would prohibit participation in aerobic exercise or would negatively impact the study
- No history of cancer, except nonmelanoma skin cancers, and in situ cervical cancers
- No eating disorders (e.g., bulimia or binge-eating disorder)
- At least one year since prior smoking
- Not planning to move away from the area during the period of the study
- No concurrent participation in any weight loss programs
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- At least 3 months since prior hormonal contraception
- Must use effective non-hormonal contraception unless participant has undergone prior tubal ligation
- Consumes no more than 7 alcoholic beverages per week
Trial locations and contacts
1 site in 1 country.
United States1 site
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104-4283
About this study
Official title: Women In Steady Exercise Research (WISER) Sister
RATIONALE: Exercise may change the risk of developing breast cancer. It is not yet known whether low-intensity exercise or high-intensity exercise is more effective in lowering the risk of breast cancer.
PURPOSE: This randomized clinical trial is studying how well exercise programs work in healthy young women at increased risk of developing breast cancer.
Read the detailed description
OBJECTIVES:
Primary
- To conduct a dose response study of low- or high-dose exercise over 5 menstrual cycles, with no concomitant dietary changes producing a caloric deficit, in healthy younger women with ≥ 18% lifetime risk for developing breast cancer.
- To determine the effects of this exercise regimen on variables known to be associated with breast mitotic activity in these participants.
Secondary
- To assess changes in other physiologic parameters associated with breast mitotic activity (i.e., urinary progesterone [pregnanediol-glucuronide, PdG] from daily first morning urine samples; follicular phase circulating [serum] levels of estradiol, progesterone, testosterone, and prolactin; follicular phase breast density [fibroglandular tissue volume] from magnetic resonance imaging; estrogen metabolites [estrone, estradiol, estriol, 2-OHE_1, 2-OHE_2, 4-OHE_1, 4-OHE_2, 16-OHE_1 and ratios]; adipokines [i.e., adiponectin and Leptin]; and body composition [i.e., % body fat, lean mass, fat mass, total mass]) in these participants.
- To assess the extent to which changes in body composition and/or body mass mediate observed changes in these participants.
- To quantify the relationship between estrogen and progesterone from daily urinary measurements with observed menstrual cycle alterations such as follicular and luteal phase length changes, and ovulatory status in these participants.
- To compare levels and exercise-induced changes in urinary estrogens, estrogen metabolites, circulating hormones, adipokines, and body size across two groups of women who differ as to breast cancer risk in an exploratory manner.
OUTLINE: Patients are stratified according to body mass index (21-29.9 vs 30-50) and gynecologic age (< 10 vs ≥ 10 years since start of menstruation). Participants are randomized to 1 of 3 intervention arms.
- Arm I (control): Participants are placed on a waiting list to receive the exercise intervention at completion of the study.
- Arm II: Participants undergo a low-intensity exercise program comprising 150 minutes of exercise per week for 20 weeks. They are given a treadmill at the beginning of the study and offered ongoing support from a certified exercise professional. Participants may exercise at home on the provided treadmill or at a gym of their choosing. Participants must maintain weekly contact with the exercise professional for the duration of the study, either by phone for brief phone counseling or at a weekly group exercise session at a participating YMCA. The exercise professional visits the participant's home for the first exercise session of each of the first 5 weeks to help individualize the intensity and duration of the exercise session and to instruct participants on the use of the exercise logs and on injury prevention.
Exercise intensity is measured by a Polar Heart Rate monitor worn by the participant to record heart rate response during exercise. Every two weeks, the exercise professional reviews downloadable heart-rate data from the monitor during the home or group exercise session, to objectively measure exercise adherence and provide guidance and emotional support to the participant.
- Arm III: Participants undergo a high-intensity exercise program that begins with 150 minutes of exercise per week and then gradually builds to 300 minutes per week over 10 weeks. Participants continue to exercise at the higher level until the end of the 20-week intervention period. Participants also undergo exercise and heart rate monitoring and brief phone counseling as in arm II.
Blood and urine samples are obtained from participants periodically before and/or during study to evaluate factors associated with breast mitotic activity and linked to breast cancer risk: urinary conjugates (i.e., E1G and PdG) by enzyme immunoassays; urinary estrogen metabolites by gas chromatography/mass spectrometry; circulating hormones (i.e., estradiol, progesterone, testosterone, and prolactin) by radioimmunoassay; and adipokines (i.e., adiponectin and leptin) by sandwich ELISA. Participants also undergo physical assessments, including periodic measures of body composition by DEXA, follicular phase breast density (fibroglandular tissue volume) by MRI, and height and weight. Aerobic fitness and physical activity levels are also assessed.
Participants complete surveys and questionnaires periodically during study to obtain information on demographics, health history, medication use, eating disorders, dietary intake, and menstrual history.
- Conditions
- Breast Cancer, Healthy, no Evidence of Disease
- Being tested
- exercise intervention, counseling intervention, gas chromatography, immunoenzyme technique, immunologic technique
- Keywords
- breast cancer, healthy, no evidence of disease
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
exercise interventionBehavioural
counseling interventionOther
gas chromatographyOther
immunoenzyme techniqueOther
immunologic techniqueOther
laboratory biomarker analysisOther
mass spectrometryOther
physiologic testingOther
questionnaire administrationOther
survey administrationOther
dual x-ray absorptometryProcedure or surgery
magnetic resonance imagingProcedure or surgery
study of high risk factorsProcedure or surgery
| Study group | Role | What they receive |
|---|---|---|
| exercise | Experimental | Not described Receives: Behavioral: exercise intervention; Other: counseling intervention; Other: gas chromatography; Other: immunoenzyme technique; Other: immunologic technique; Other: laboratory biomarker analysis; Other: mass spectrometry; Other: physiologic testing; Other: questionnaire administration; Other: survey administration; Procedure: dual x-ray absorptometry; Procedure: magnetic resonance imaging; Procedure: study of high risk factors |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in the area under the curve for urinary estrogen (E1G-AUC) adjusted for cycle length
Secondary outcomes (4)
Effects of exercise on variables known to affect or reflect mitogenic activity as related to breast cancer risk
Changes in other physiologic parameters associated with breast mitotic activity
Extent to which changes in body composition and body mass mediate observed changes in E1G-AUC
Relationship between estrogen and progesterone from daily urinary measurements with observed menstrual cycle alterations (i.e., follicular and luteal phase length changes, and ovulatory status)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 May 2009 (estimated)
- Study startOct 2008
- Primary completionMay 2012
- Study completion20 May 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Abramson Cancer Center at Penn MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- Single blind
- Enrolment
- 183 participants (actual)
Sponsor and investigators
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Katie Schmitz, PhD, Principal investigator, Abramson Cancer Center at Penn Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00892515
- Sponsor's protocol ID
- CDR0000617105
- Other IDs
- UPCC-807822, UPCC-09108
- Status last verified
- Apr 2020
- First submitted
- 1 May 2009
- Last updated
- 16 Apr 2020
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Boyer AL, Arikawa AY, Schmitz KH, Sturgeon KM. Association of Inflammatory Diets with Inflammatory Biomarkers in Women at High Genetic Risk for Breast Cancer. Nutr Cancer. 2022;74(3):816-819. doi: 10.1080/01635581.2021.1986554. Epub 2021 Oct 6.
PubMed 34615429
Study at a glance
From the registry record, last updated by the sponsor on 16 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Women In Steady Exercise Research (WISER) Sister
- ClinicalTrials.gov ID
- NCT00892515
- Acronym / sponsor ID
- CDR0000617105
- Conditions
- Breast Cancer, Healthy, no Evidence of Disease
- Keywords
- breast cancer, healthy, no evidence of disease
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 183 participants (actual)
- Lead sponsor
- Abramson Cancer Center at Penn MedicineUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Oct 2008
- Primary completion
- May 2012 (actual)
- Study completion
- 20 May 2016 (actual)
- First posted
- 4 May 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Exercise may change the risk of developing breast cancer. It is not yet known whether low-intensity exercise or high-intensity exercise is more effective in lowering the risk of breast cancer.
PURPOSE: This randomized clinical trial is studying how well exercise programs work in healthy young women at increased risk of developing breast cancer.
Detailed description
OBJECTIVES:
Primary
- To conduct a dose response study of low- or high-dose exercise over 5 menstrual cycles, with no concomitant dietary changes producing a caloric deficit, in healthy younger women with ≥ 18% lifetime risk for developing breast cancer.
- To determine the effects of this exercise regimen on variables known to be associated with breast mitotic activity in these participants.
Secondary
- To assess changes in other physiologic parameters associated with breast mitotic activity (i.e., urinary progesterone [pregnanediol-glucuronide, PdG] from daily first morning urine samples; follicular phase circulating [serum] levels of estradiol, progesterone, testosterone, and prolactin; follicular phase breast density [fibroglandular tissue volume] from magnetic resonance imaging; estrogen metabolites [estrone, estradiol, estriol, 2-OHE_1, 2-OHE_2, 4-OHE_1, 4-OHE_2, 16-OHE_1 and ratios]; adipokines [i.e., adiponectin and Leptin]; and body composition [i.e., % body fat, lean mass, fat mass, total mass]) in these participants.
- To assess the extent to which changes in body composition and/or body mass mediate observed changes in these participants.
- To quantify the relationship between estrogen and progesterone from daily urinary measurements with observed menstrual cycle alterations such as follicular and luteal phase length changes, and ovulatory status in these participants.
- To compare levels and exercise-induced changes in urinary estrogens, estrogen metabolites, circulating hormones, adipokines, and body size across two groups of women who differ as to breast cancer risk in an exploratory manner.
OUTLINE: Patients are stratified according to body mass index (21-29.9 vs 30-50) and gynecologic age (< 10 vs ≥ 10 years since start of menstruation). Participants are randomized to 1 of 3 intervention arms.
- Arm I (control): Participants are placed on a waiting list to receive the exercise intervention at completion of the study.
- Arm II: Participants undergo a low-intensity exercise program comprising 150 minutes of exercise per week for 20 weeks. They are given a treadmill at the beginning of the study and offered ongoing support from a certified exercise professional. Participants may exercise at home on the provided treadmill or at a gym of their choosing. Participants must maintain weekly contact with the exercise professional for the duration of the study, either by phone for brief phone counseling or at a weekly group exercise session at a participating YMCA. The exercise professional visits the participant's home for the first exercise session of each of the first 5 weeks to help individualize the intensity and duration of the exercise session and to instruct participants on the use of the exercise logs and on injury prevention.
Exercise intensity is measured by a Polar Heart Rate monitor worn by the participant to record heart rate response during exercise. Every two weeks, the exercise professional reviews downloadable heart-rate data from the monitor during the home or group exercise session, to objectively measure exercise adherence and provide guidance and emotional support to the participant.
- Arm III: Participants undergo a high-intensity exercise program that begins with 150 minutes of exercise per week and then gradually builds to 300 minutes per week over 10 weeks. Participants continue to exercise at the higher level until the end of the 20-week intervention period. Participants also undergo exercise and heart rate monitoring and brief phone counseling as in arm II.
Blood and urine samples are obtained from participants periodically before and/or during study to evaluate factors associated with breast mitotic activity and linked to breast cancer risk: urinary conjugates (i.e., E1G and PdG) by enzyme immunoassays; urinary estrogen metabolites by gas chromatography/mass spectrometry; circulating hormones (i.e., estradiol, progesterone, testosterone, and prolactin) by radioimmunoassay; and adipokines (i.e., adiponectin and leptin) by sandwich ELISA. Participants also undergo physical assessments, including periodic measures of body composition by DEXA, follicular phase breast density (fibroglandular tissue volume) by MRI, and height and weight. Aerobic fitness and physical activity levels are also assessed.
Participants complete surveys and questionnaires periodically during study to obtain information on demographics, health history, medication use, eating disorders, dietary intake, and menstrual history.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- Single blind
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| exercise | Experimental | Behavioral: exercise intervention, Other: counseling intervention, Other: gas chromatography, Other: immunoenzyme technique, Other: immunologic technique, Other: laboratory biomarker analysis, Other: mass spectrometry, Other: physiologic testing, Other: questionnaire administration, Other: survey administration, Procedure: dual x-ray absorptometry, Procedure: magnetic resonance imaging, Procedure: study of high risk factors |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| exercise intervention | Behavioural | exercise |
| counseling intervention | Other | exercise |
| gas chromatography | Other | exercise |
| immunoenzyme technique | Other | exercise |
| immunologic technique | Other | exercise |
| laboratory biomarker analysis | Other | exercise |
| mass spectrometry | Other | exercise |
| physiologic testing | Other | exercise |
| questionnaire administration | Other | exercise |
| survey administration | Other | exercise |
| dual x-ray absorptometry | Procedure or surgery | exercise |
| magnetic resonance imaging | Procedure or surgery | exercise |
| study of high risk factors | Procedure or surgery | exercise |
Primary outcome
Change in the area under the curve for urinary estrogen (E1G-AUC) adjusted for cycle length
4 secondary outcomes
Effects of exercise on variables known to affect or reflect mitogenic activity as related to breast cancer risk
Changes in other physiologic parameters associated with breast mitotic activity
Extent to which changes in body composition and body mass mediate observed changes in E1G-AUC
Relationship between estrogen and progesterone from daily urinary measurements with observed menstrual cycle alterations (i.e., follicular and luteal phase length changes, and ovulatory status)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Apr 2020.
- Derived from this study: PubMed 34615429Boyer AL, Arikawa AY, Schmitz KH, Sturgeon KM. Association of Inflammatory Diets with Inflammatory Biomarkers in Women at High Genetic Risk for Breast Cancer. Nutr Cancer. 2022;74(3):816-819. doi: 10.1080/01635581.2021.1986554. Epub 2021 Oct 6.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Katie Schmitz, PhD principal investigator
Abramson Cancer Center at Penn Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing exercise intervention, counseling intervention and gas chromatography in people with Breast Cancer and Healthy, no Evidence of Disease, run by Abramson Cancer Center at Penn Medicine at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in the area under the curve for urinary estrogen (E1G-AUC) adjusted for cycle length. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00892515, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Apr 2020.